SCHEMBL6600779

SCHEMBL6600779

CCOc1cc(C2=NN(C(=O)c3ccc(NC(=O)c4ccccn4)cc3)CCC2)ccc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.48
AURKB Q96GD4 1/20 0.47
CFTR P13569 6/20 0.46
GRM4 Q14833 3/20 0.46
MITF O75030 1/20 0.46
PKM P14618 1/20 0.46
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PGR P06401 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601572 0.94 NPC1 (0.56) NPC1SMN1; SMN2KDM4ERAB9AALDH1A1
SCHEMBL6602816 0.92 NPC1 (0.48) NPC1SMN1; SMN2KDM4ERAB9AALDH1A1
SCHEMBL6601547 0.92 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1POLBCFTRMAPT
SCHEMBL6587589 0.91 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1POLBMAPTMEN1
SCHEMBL6602654 0.91 RAB9A (0.47) NPC1SMN1; SMN2RAB9AALDH1A1POLB
SCHEMBL6601535 0.90 CFTR (0.45) ALDH1A1POLBCFTRPGR
SCHEMBL6602107 0.89 NPC1 (0.48) NPC1SMN1; SMN2KDM4ERAB9AALDH1A1
SCHEMBL6581226 0.89 PGR (0.54) SMN1; SMN2ALDH1A1POLBCFTRPKM
SCHEMBL6601230 0.89 HTT (0.47) SMN1; SMN2KDM4EALDH1A1POLBCFTR
SCHEMBL6603355 0.88 PDE4D (0.51) NPC1SMN1; SMN2KDM4ERAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0922036-B1 ARYLALKANOYL PYRIDAZINES MERCK PATENT GMBH (DE) 2004-03-24 EP disclosed
US-6479494-B1 THEY INHIBIT SELECTIVELY PHOSPHODIESTERASE IV, WHICH CAUSES AN INCREASE OF THE INTRACELLULAR CAMP LEVEL AS CAMP INHIBITS BONE DECREASING CELLS AND STIMULATES BONE INCREASING CELLS FOR TREATMENT OF OSTEOPOROSIS MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-11-12 US disclosed
EP-1143944-A3 USE OF ARYLALKANOYLPYRIDAZINES MERCK PATENT GmbH (DE) 2002-09-11 EP disclosed
EP-1143944-A2 USE OF ARYLALKANOYLPYRIDAZINES MERCK PATENT GmbH (DE) 2001-10-17 EP disclosed
WO-2000059484-A2 USE OF ARYLALKANOYLPYRIDAZINES MERCK PATENT GMBH (DE) 2000-10-12 WO disclosed